Company Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.
In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications.
The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International.
Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
| Country | United States |
| Founded | 1987 |
| IPO Date | Nov 18, 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Todd Davis |
Contact Details
Address: 555 Heritage Drive, Suite 200 Jupiter, Florida 33458 United States | |
| Phone | 858 550 7500 |
| Website | ligand.com |
Stock Details
| Ticker Symbol | LGND |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000886163 |
| CUSIP Number | 53220K504 |
| ISIN Number | US53220K5048 |
| Employer ID | 77-0160744 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Todd C. Davis Ph.D. | Chief Executive Officer and Director |
| Octavio Espinoza | Chief Financial Officer |
| Andrew T. Reardon J.D. | Chief Legal Officer and Secretary |
| Paul J. Hadden | Senior Vice President of Investments and Business Development |
| Michael Jeong | Head of Investor Relations |
| Dr. Keith Marschke | Senior Vice President of Biology and Scientific Affairs |
| Dr. Vincent D. Antle | Senior Vice President of Technical Operations and QA - Capitsol |
| Patrick Lucy | Senior Vice President and CBO Protein Expression Business |
| Dr. Karen R. Reeves M.D. | Senior Vice President of Investments and Head of Clinical Strategy |
| Richard B. Baxter | Senior Vice President of Investment Operation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Sep 23, 2024 | 144 | Filing |
| Sep 23, 2024 | 144 | Filing |
| Sep 20, 2024 | 144 | Filing |
| Sep 20, 2024 | 144 | Filing |